drugset / Trial / NCT00591253
Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the effectiveness and safety of azilsartan medoxomil compared to placebo, once daily (QD), in African-American participants with essential hypertension.
Timeline
- Start
- 2007-10
- Primary completion
- 2009-04
- Completion
- 2009-04
Outcome
Met primary endpoint
registry Azilsartan Medoxomil 40 mg QD vs Placebo QD; p = 0.001; Mean Difference (Final Values) -5.00 (95% CI -7.97 to -2.04) NCT00591253 ↗
registry Azilsartan Medoxomil 80 mg QD vs Placebo QD; p <0.001; Mean Difference (Final Values) -7.78 (95% CI -10.69 to -4.86) NCT00591253 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azilsartan medoxomil | Other / unclassified | 40 mg | Oral |
| Subject | Azilsartan medoxomil | Other / unclassified | 80 mg | Oral |